Skip to main content
SpringerLink
Log in

Empirical Antibiotic Therapy for Patients with Severe Sepsis and Septic Shock

  • Chapter
The Sepsis Text

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Astiz ME, Rackow EC. Septic shock. Lancet 1998; 351:1501–1505

    Article  PubMed  CAS  Google Scholar 

  2. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207–214

    Article  PubMed  CAS  Google Scholar 

  3. Shenep JL. Septic shock. Adv Pediatr Infect Dis 1996; 12:209–241

    PubMed  CAS  Google Scholar 

  4. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481–1483

    PubMed  CAS  Google Scholar 

  5. Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gramnegative rod bacteremia. Chemotherapy 1978; 24:45–54

    PubMed  CAS  Google Scholar 

  6. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344–355

    PubMed  CAS  Google Scholar 

  7. Young LS. Sepsis syndrome. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and Practice of Infectious Diseases. Churchill Livingstone, New York, 1995: pp 690–705

    Google Scholar 

  8. Calandra T, Cometta A. Antibiotic therapy for gram-negative bacteremia. Infect Dis Clin North Am 1991; 5:817–834

    PubMed  CAS  Google Scholar 

  9. Rangel-Frausto MS. The epidemiology of bacterial sepsis. Infect Dis Clin North Am 1999; 13:299–312

    PubMed  CAS  Google Scholar 

  10. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1997, issued May 1997. A report from the NNIS System. Am J Infect Control 1997; 25:477–487

    Google Scholar 

  11. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584–602

    PubMed  CAS  Google Scholar 

  12. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med 2001; 27 (suppl 1): S33–S48

    PubMed  Google Scholar 

  13. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239–244

    PubMed  CAS  Google Scholar 

  14. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998; 30:121–129

    PubMed  CAS  Google Scholar 

  15. McCabe WR, Jackson GG. Gram negative bacteremia. Arch Intern Med 1962; 110:92–100

    Google Scholar 

  16. Bryant RE, Hood AF, Hood CE, et al. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med 1971; 127:120–128

    Article  PubMed  CAS  Google Scholar 

  17. Young LS, Martin WJ, Meyer RD, et al. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med 1977; 86:456–471

    PubMed  CAS  Google Scholar 

  18. Freid MA, Vosti KL. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med 1968; 121:418–423

    Article  PubMed  CAS  Google Scholar 

  19. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127–1133

    PubMed  CAS  Google Scholar 

  20. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585–590

    PubMed  CAS  Google Scholar 

  21. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156:2121–6.

    Article  PubMed  CAS  Google Scholar 

  22. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174:529–536

    PubMed  CAS  Google Scholar 

  23. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379–386

    Article  PubMed  CAS  Google Scholar 

  24. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146–155

    Article  PubMed  CAS  Google Scholar 

  25. Nguyen MH, Peacock JE, Jr., Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429–2435

    Article  PubMed  CAS  Google Scholar 

  26. Calandra T, Glauser MP. Immunocompromised animal models for the study of antibiotic combinations. Am J Med 1986; 80:45–52

    PubMed  CAS  Google Scholar 

  27. Gribble MJ, Chow AW, Naiman SC, et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 1983; 24:388–393

    PubMed  CAS  Google Scholar 

  28. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38:1309–1313

    PubMed  CAS  Google Scholar 

  29. Oblinger MJ, Bowers JT, Sande MA, et al. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections. Rev Infect Dis 1982; 4 (Suppl):S639–S649

    PubMed  Google Scholar 

  30. Arich C, Gouby A, Bengler C, et al. Comparison of the efficacy of cefotaxime alone and the combination cefazolin-tobramycin in the treatment of enterobacterial septicemia. Pathol Biol 1987; 35:613–615

    PubMed  CAS  Google Scholar 

  31. McCormick PA, Greenslade L, Kibbler CC, et al. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepatology 1997; 25:833–836

    Article  PubMed  CAS  Google Scholar 

  32. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987; 317:1692–1698

    Google Scholar 

  33. Mouton Y, Deboscker Y, Bazin C, et al. Prospective, randomized, controlled study of imipenem-cilastatin versus cefotaxime-amikacin in the treatment of lower respiratory tract infection and septicemia at intensive care units. Presse Medicale 1990; 19:607–612

    CAS  Google Scholar 

  34. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995; 36 (Suppl A):157–166

    PubMed  CAS  Google Scholar 

  35. Klastersky J, Meunier-Carpentier F, Prevost JM. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci 1977; 273:157–167

    PubMed  CAS  Google Scholar 

  36. Hanson B, Coppens L, Klastersky J. Comparative studies of ticarcillin and mezlocillin plus sisomicin in Gram-negative bacillary bacteraemia and bronchopneumonia. J Antimicrob Chemother 1982; 10:335–341

    PubMed  CAS  Google Scholar 

  37. Beaucaire G. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. J Chemother 1995; 7 Suppl 2:165–173

    PubMed  CAS  Google Scholar 

  38. Klastersky J, Coppens L, Meunier-Carpentier F, et al. Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study. Antimicrob Agents Chemother 1980; 18:437–442

    PubMed  CAS  Google Scholar 

  39. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995; 36 (Suppl A): 145–156

    PubMed  CAS  Google Scholar 

  40. White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2:697–701

    PubMed  CAS  Google Scholar 

  41. Extermann M, Regamey C, Humair L, et al. Initial treatment of sepsis in non-neutropenic patients: ceftazidime alone versus ‘best guess’ combined antibiotic therapy. Chemotherapy 1995;41:306–315

    PubMed  CAS  Google Scholar 

  42. Hess U, Bohme C, Rey K, et al. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6:402–409

    Article  PubMed  CAS  Google Scholar 

  43. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992; 36:2766–2773

    PubMed  CAS  Google Scholar 

  44. Eklund AE, Nord CE. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother 1993; 31 (Suppl A):79–85

    PubMed  Google Scholar 

  45. Polk HC, Jr., Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Am Surg 1993; 59:598–605

    PubMed  Google Scholar 

  46. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966–2972

    PubMed  CAS  Google Scholar 

  47. Hammerberg O, Kurnitzki C, Watts J, et al. Randomized trial using piperacillin versus ampicillin and amikacin for treatment of premature neonates with risk factors for sepsis. Eur J Clin Microbiol Infect Dis 1989; 8:241–244

    Article  PubMed  CAS  Google Scholar 

  48. Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 2000; 44:2028–2333

    Article  PubMed  CAS  Google Scholar 

  49. Gudiol F, Pallares R, Ariza X, et al. Comparative clinical evaluation of aztreonam versus aminoglycosides in gram-negative septicaemia. J Antimicrob Chemother 1986; 17:661–671

    PubMed  CAS  Google Scholar 

  50. Rabinad E, Bosch-Perez A. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. Chemotherapy 1989; 35(Suppl 1):1–7

    PubMed  Google Scholar 

  51. Norrby SR, Geddes AM. Efficacy of cefpirome in the treatment of septicaemia. Scand J Infect Dis 1993; 91:51–59

    CAS  Google Scholar 

  52. Schrank JH, Jr., Kelly JW, McAllister CK. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis 1995; 20:56–58

    PubMed  Google Scholar 

  53. Norrby SR, Geddes AM, Shah PM. Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Multicentre Study Group. J Antimicrob Chemother 1998; 42:503–509

    Article  PubMed  CAS  Google Scholar 

  54. Hartenauer U, Weilemann LS, Bodmann KF, et al. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect 1990; 15 (Suppl A):61–64

    PubMed  Google Scholar 

  55. Krumpe PE, Cohn S, Garreltes J, et al. Intravenous and oral mono-or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. J Antimicrob Chemother 1999; 43 (Suppl A): 117–128

    PubMed  CAS  Google Scholar 

  56. C DC. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995; 44:1–13

    Google Scholar 

  57. Rubin LG, Tucci V, Cercenado E, et al. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992; 13:700–705

    Article  PubMed  CAS  Google Scholar 

  58. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16:750–755

    PubMed  CAS  Google Scholar 

  59. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20:1531–1534

    PubMed  CAS  Google Scholar 

  60. Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996; 154:617–624

    PubMed  CAS  Google Scholar 

  61. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997; 278:234–240

    Article  PubMed  CAS  Google Scholar 

  62. Nguyen MH, Peacock JE, Jr., Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617–623

    PubMed  CAS  Google Scholar 

  63. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331:1325–1330

    Article  PubMed  CAS  Google Scholar 

  64. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337–345

    Article  PubMed  CAS  Google Scholar 

  65. Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24:426–432

    Article  PubMed  CAS  Google Scholar 

  66. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996; 101:170–176

    Article  PubMed  CAS  Google Scholar 

  67. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662–678

    Article  PubMed  CAS  Google Scholar 

  68. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77:657–662

    Article  PubMed  CAS  Google Scholar 

  69. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073–1081

    PubMed  CAS  Google Scholar 

  70. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38:547–557

    PubMed  CAS  Google Scholar 

  71. Caldwell JW, Singh S, Johnson RH. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. J Antimicrob Chemother 1999; 43 (Suppl A): 129–34

    PubMed  CAS  Google Scholar 

  72. Struelens MJ, Byl B, Govaerts D, et al. Modification of antibiotic policy associated with decrease in antibiotic-resistant Gram-negative bacilli in an intensive care unit. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.

    Google Scholar 

  73. Hamza L, Benali A, Cheval C, et al. Effect of an antibiotic intervention upon resistance of Enterobacteriaceae producing inducible cephalosporinases in two intensive care units of a 430 bed hospital. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000.

    Google Scholar 

Download references

Authors
  1. Pierre-Yves Bochud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel P. Glauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean Carlet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thierry Calandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme University Hospital, Brussels, Belgium

    Jean-Louis Vincent M.D.

  2. Service de Réanimation Polyvalente, Hôpital Saint-Joseph, Paris, France

    Jean Carlet M.D.

  3. Division of Infectious Diseases, The Memorial Hospital of Rhode Island, Pawtucket, RI

    Steven M. Opal M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Bochud, PY., Glauser, M.P., Carlet, J., Calandra, T. (2002). Empirical Antibiotic Therapy for Patients with Severe Sepsis and Septic Shock. In: Vincent, JL., Carlet, J., Opal, S.M. (eds) The Sepsis Text. Springer, Boston, MA. https://doi.org/10.1007/0-306-47664-9_31

Download citation

  • DOI: https://doi.org/10.1007/0-306-47664-9_31

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-7923-7620-0

  • Online ISBN: 978-0-306-47664-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation